Learn About Rhabdomyosarcoma Embryonal

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Rhabdomyosarcoma Embryonal Local Doctors?
WT
Dr. William D. Tap
Hematology Oncology
Elite
Highly rated in
36
conditions
Hematology Oncology

Memorial Sloan Kettering Cancer Center

1275 York Ave 
New York, NY 10065

William Tap is a Hematologist Oncology doctor in New York, New York. Dr. Tap has been practicing medicine for over 22 years and is rated as an Elite doctor by MediFind in the treatment of Rhabdomyosarcoma Embryonal. He is also highly rated in 36 other conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor, and Synovial Sarcoma. He is licensed to treat patients in New York and California. Dr. Tap is currently accepting new patients.

View Profile
AF
Andrea L. Ferrari
Andrea L. Ferrari
Elite
Highly rated in
29
conditions

Fondazione IRCCS Istituto Nazionale Dei Tumori

Pediatric Oncology Unit 
Milan, IT 

Andrea Ferrari is in Milan, Italy. Ferrari is rated as an Elite expert by MediFind in the treatment of Rhabdomyosarcoma Embryonal. She is also highly rated in 29 other conditions, according to our data. Her top areas of expertise are Rhabdomyosarcoma, Rhabdomyosarcoma Embryonal, Synovial Sarcoma, and Adult Soft Tissue Sarcoma.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
SS
Dr. Scott M. Schuetze
Oncology
Elite
Highly rated in
29
conditions
Oncology

Michigan Medicine

University Hospital

1500 E Medical Center Dr 
Ann Arbor, MI 48109

Scott Schuetze is an Oncologist in Ann Arbor, Michigan. Dr. Schuetze has been practicing medicine for over 29 years and is rated as an Elite doctor by MediFind in the treatment of Rhabdomyosarcoma Embryonal. He is also highly rated in 29 other conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Liposarcoma, and Leiomyosarcoma. He is licensed to treat patients in Michigan. Dr. Schuetze is currently accepting new patients.

View Profile
View All Doctors
What are the Latest Advances for Rhabdomyosarcoma Embryonal?
Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study.
Condition: Soft Tissue Sarcoma
Journal: BMC cancer
Treatment Used: Nab-Paclitaxel plus PD-1 Inhibitor
Number of Patients: 28
Published: January 13, 2022
View publication
Summary: Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study.
Establishment and Characterization of a Cell Line (S-RMS1) Derived from an Infantile Spindle Cell Rhabdomyosarcoma with SRF-NCOA2 Fusion Transcript.
Journal: International journal of molecular sciences
Published: June 02, 2021
View publication
Summary: Establishment and Characterization of a Cell Line (S-RMS1) Derived from an Infantile Spindle Cell Rhabdomyosarcoma with SRF-NCOA2 Fusion Transcript.
Tired of the same old research?
Check Latest Advances
Management of Rhabdomyosarcoma in Pediatric Patients.
Condition: Rhabdomyosarcoma in Pediatric Patients
Journal: Surgical oncology clinics of North America
Treatment Used: Chemotherapy, Surgery and/or Radiotherapy
Number of Patients: 0
Published: March 12, 2021
View publication
Summary: Management of Rhabdomyosarcoma in Pediatric Patients.
View All Latest Advances
What are the latest Rhabdomyosarcoma Embryonal Clinical Trials?
A Pilot Phase II Trial Of Irinotecan Plus Carboplatin, And Irinotecan Maintenance Therapy (High-Risk Patients Only), Integrated Into The Upfront Therapy Of Newly Diagnosed Patients With Intermediate - And High-Risk Rhabdomyosarcoma
Who is this study for: Adult patients with with intermediate- and high-risk rhabdomyosarcoma
Status: Active, not recruiting
Start Date: October 2003
Intervention Type: Drug, Biological, Procedure, Radiation
Study Drugs: Dexrazoxane, Irinotecan, Carboplatin, Podofilox, Daunorubicin, Doxorubicin, Ifosfamide, Etoposide
Phase: Phase 2
View Trial
Summary: RATIONALE: Drugs used in chemotherapy, such as irinotecan and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.~PURPOSE: This phase II trial is studying how well giving irinotecan together with carboplatin as upfront window therapy (first-line therapy) works in treating patients with newly diagnos...
Match to trials
Find the right clinical trials for you in under a minute
Get started
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Who is this study for: Patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that have spread to other places in the body and have come back or do not respond to treatment
Status: Recruiting
Start Date: July 24, 2017
Intervention Type: Drug
Study Drugs: Larotrectinib
Phase: Phase 2
View Trial
Summary: This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that have spread to other places in the body and have come back or do not respond to treatment. Larotrectinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
View All Clinical Trials